There are currently 51 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. The states with the highest number of trials for Amyotrophic Lateral Sclerosis participants are California, Florida, Pennsylvania and New York.
RAPA-501 Therapy for ALS
Recruiting
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Amyotrophic Lateral Sclerosis
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Recruiting
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Gender:
ALL
Ages:
10 years and above
Trial Updated:
11/08/2024
Locations: University of California San Diego, La Jolla, California +24 locations
Conditions: Amyotrophic Lateral Sclerosis
Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/17/2024
Locations: University of California, Orange, California +16 locations
Conditions: Amyotrophic Lateral Sclerosis
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
Recruiting
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of California Irvine, Irvine, California +9 locations
Conditions: Amyotrophic Lateral Sclerosis
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Recruiting
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS There i... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/01/2024
Locations: Loma Linda University, Loma Linda, California
Conditions: Amyotrophic Lateral Sclerosis
Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study
Recruiting
The goal of this clinical trial is to learn how doing mechanical insufflation (MI) using a mechanical insufflator-exsufflator (MI-E) device affects breathing in early amyotrophic lateral sclerosis (ALS). This will be a single-center, single-arm study of MI in 20 patients with ALS at Penn. Based on prior research, we believe that 6-months of MI may slow decline in cough strength, measured as peak cough flow (PCF). Participants will perform MI using a device designed for mechanical insufflation-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Amyotrophic Lateral Sclerosis, Chronic Respiratory Failure, Airway Clearance Impairment, Neuromuscular Diseases
Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis
Recruiting
The aim of this study is to understand how well a 6-week virtual yogic breathing exercise program (YBEP) will improve breathing, speech, and emotional well-being in people with amyotrophic lateral sclerosis (ALS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/21/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Amyotrophic Lateral Sclerosis, Myasthenia Gravis
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
Recruiting
The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2024
Locations: 354 School of Health Professions Building, Birmingham, Alabama
Conditions: Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
Recruiting
The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish a repository for future investigations of genetic contributions to ALS pathogenesis. Blood samples for DNA extraction also would be collected from control subjects with no personal or family history of ALS phenotypes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis
Intermuscular Coherence as a Biomarker for ALS
Recruiting
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of... Read More
Gender:
ALL
Ages:
Between 20 years and 90 years
Trial Updated:
08/02/2024
Locations: University of California Center for Clinical Research, Irvine, California +3 locations
Conditions: Amyotrophic Lateral Sclerosis
Investigation on the Cortical Communication (CortiCom) System
Recruiting
The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In each participant, the grid(s) will be implanted over areas of cortex that encode speech and upper extremity movement.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/01/2024
Locations: Johns Hopkins Medicine, Baltimore, Maryland
Conditions: Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
Digital Assessment of Speech and Fine Motor Control in ALS
Recruiting
This is a single-session, case-control study that incorporates digital tools for assessing speech and motor function in motor neuron disease. Patients with motor neuron disease (including amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and progressive muscular atrophy (PMA)) and age-matched healthy controls will be enrolled. Subjects will complete a speech and handwriting assessment during the study visit on a tablet computer (BioSensics LLC, Newton, MA). We will explore wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy